Begoña P. Valderrama

Author

Hospital Universitario Virgen del Rocío ORCID

Also Known As

B Valderrama, B. P. Valderrama, B. Perez Valderrama, B. Pérez Valderrama, B. Valderrama, B.P. Valderrama, Begona P. Valderrama, Begona Perez Valderrama, Begona Pérez Valderrama, Begoña P Valderrama

164

Publications

6.4K

Citations

H-Index

Concepts

All Affiliations

Hospital Universitario Virgen del Rocío Institut Gustave Roussy Université Paris-Saclay Queen Mary University of London Samsung Medical Center

About

Begoña P. Valderrama is an author at Hospital Universitario Virgen del Rocío specializing in oncology, urology, and medicine.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	26	1.4K
2	Pathology	8	8	135
3	Immunology	3	3	79
4	Health Sciences	2	2	103
5	Biostatistics	1	1	22

Begoña P. Valderrama

Publications

5.7K

Citations

H-Index

Page 1

	Year	Citations
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma Thomas Powles, Se Hoon Park, Éric Voog, New England Journal of Medicine	2020	1.4K
Adjuvant Nivolumab versus Placebo in Muscle-Invasive Urothelial Carcinoma Dean F. Bajorin, J. Alfred Witjes, Jürgen E. Gschwend, New England Journal of Medicine	2021	968
Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, New England Journal of Medicine	2024	764
Bladder cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up Tom Powles, Joaquim Bellmunt, Éva Compérat, Annals of Oncology UrologySurgical OncologyGenitourinary CancerMedicineCancer Management	2021	492
Nivolumab plus Gemcitabine–Cisplatin in Advanced Urothelial Carcinoma Michiel S. van der Heijden, Guru Sonpavde, Thomas Powles, New England Journal of Medicine	2023	421
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma Yohann Loriot, Nobuaki Matsubara, Se Hoon Park, New England Journal of Medicine	2023	255
Avelumab First-Line Maintenance for Advanced Urothelial Carcinoma: Results From the JAVELIN Bladder 100 Trial After ≥2 Years of Follow-Up Thomas Powles, Se Hoon Park, Claudia Caserta, Journal of Clinical Oncology	2023	192
ESMO Clinical Practice Guideline interim update on first-line therapy in advanced urothelial carcinoma Thomas Powles, Joaquim Bellmunt, Éva Compérat, Annals of Oncology First-line TherapySurgical OncologyUrologyGenitourinary CancerMedicine	2024	135
LBA6 EV-302/KEYNOTE-A39: Open-label, randomized phase III study of enfortumab vedotin in combination with pembrolizumab (EV+P) vs chemotherapy (Chemo) in previously untreated locally advanced metastatic urothelial carcinoma (la/mUC) Thomas Powles, Begoña P. Valderrama, Shilpa Gupta, Annals of Oncology UrologyGenitourinary CancerMedicineEnfortumab VedotinImmune Checkpoint Inhibitor	2023	131
Maintenance avelumab + best supportive care (BSC) versus BSC alone after platinum-based first-line (1L) chemotherapy in advanced urothelial carcinoma (UC): JAVELIN Bladder 100 phase III interim analysis. Thomas Powles, Se Hoon Park, Éric Voog, Journal of Clinical Oncology Lba1 BackgroundCancer ManagementPharmacotherapyMetronomic ChemotherapyGynecology Oncology	2020	87

Page 1